drugset
drugset / Trial / NCT04569838

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

NCT04569838 ↗

Phase 2 Completed 91 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.

Timeline

Start
2012-05
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 100 mg/m2 Intravenous
Subject Bendamustine Small molecule 120 mg/m2 Intravenous

Indications

indolent B-cell non-Hodgkin lymphoma